Text Size

Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects

This study has been completed.
Sponsor:
Collaborators:
The Danish Obesity Research Centre
Nordic Centre of Excellence
Arla Foods
Information provided by:
Aarhus University Hospital
ClinicalTrials.gov Identifier:
NCT00809874
First received: December 16, 2008
Last updated: November 9, 2009
Last verified: November 2009
History of Changes
  Purpose

The purpose of this study is to determine the effects of dietary protein on blood lipids and gut hormones after a fat-rich meal.

Hypothesis: Certain dietary proteins reduce the amount of fat circulating in the blood stream following a fat rich meal. The effect is dependant of both the quality and the quantity of protein ingested.


Condition Intervention
Postprandial Lipaemia
Postprandial Incretins
Postprandial Inflammation
 Dietary Supplement: Casein
Dietary Supplement: Whey Isolate
Dietary Supplement: Whey Hydrolysate
Dietary Supplement: Alphalact-Albumin

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects

Resource links provided by NLM:

Drug Information available for: Casein
U.S. FDA Resources

Further study details as provided by Aarhus University Hospital:

Primary Outcome Measures:
  • Triglyceride [ Time Frame: 0h- 1h- 2h- 4h- 6h- 7h- 8h postprandial ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incretins [ Time Frame: 0h -1h -2h -4h -6h -7h -8h Postprandial ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: February 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Casein Dietary Supplement: Casein
Active Comparator: Whey Isolate Dietary Supplement: Whey Isolate
Active Comparator: Whey Hydrolysate Dietary Supplement: Whey Hydrolysate
Active Comparator: Alphalact-Albumin Dietary Supplement: Alphalact-Albumin

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI >30 kg/m2 & <45 kg/m2

Exclusion Criteria:

  • Diabetes
  • lipid lowering drugs
  • Liver-, Kidney- and/or Heart Disease
  • Serious Hypertension (160/110)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00809874

Locations
Denmark
Department of Clinical Nutrion
Aarhus, Denmark, 8000
Sponsors and Collaborators
Aarhus University Hospital
The Danish Obesity Research Centre
Nordic Centre of Excellence
Arla Foods
Investigators
Principal Investigator: K Hermansen, Professor, MD Department of Endocrinology and Metabolism, Aarhus University Hospital
  More Information

No publications provided

Responsible Party: Kjeld Hermansen, Professor, Chief Physician, MD, Dr.Med.Sci, Department of Endocrinology And Metabolism, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT00809874     History of Changes
Other Study ID Numbers: CERN-PPL-JHJ
Study First Received: December 16, 2008
Last Updated: November 9, 2009
Health Authority: Denmark: Ethics Committee

Keywords provided by Aarhus University Hospital:
Postprandial Period
Postprandial Lipaemia
Incretins
Subclinical Inflammation
 Obesity
Atherosclerosis
Triglyceride
Lipoproteins

Additional relevant MeSH terms:
Hyperlipidemias
Inflammation
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Pathologic Processes
Caseins
 Incretins
Chelating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 22, 2013